daurismo
pfizer europe ma eeig - glasdegib maleate - kyrningahvítblæði, mergbólga, bráð - Æxlishemjandi lyf - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
felden hlaup 0,5 %
pfizer aps - piroxicamum inn - hlaup - 0,5 %
lopid hart hylki 300 mg
pfizer aps - gemfibrozilum inn - hart hylki - 300 mg
lopid filmuhúðuð tafla 600 mg
pfizer aps - gemfibrozilum inn - filmuhúðuð tafla - 600 mg
ticovac stungulyf, dreifa 0,5 ml
pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,5 ml
ticovac junior stungulyf, dreifa 0,25 ml
pfizer aps - tbe antigen virus - stungulyf, dreifa - 0,25 ml
pro-epanutin stungulyf, lausn/innrennslisþykkni, lausn 50 mg fe/ml
pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml
caverject dual stungulyfsstofn og leysir, lausn 10 míkróg
pfizer aps - alprostadilum inn - stungulyfsstofn og leysir, lausn - 10 míkróg
caverject dual stungulyfsstofn og leysir, lausn 20 míkróg
pfizer aps - alprostadilum inn - stungulyfsstofn og leysir, lausn - 20 míkróg
cytotec tafla 0,2 mg
pfizer aps - misoprostolum inn - tafla - 0,2 mg